News
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially
Novartis Stock: Stellar Q1 Results Exceed Expectations
Novartis delivered an impressive start to 2025, with first-quarter figures substantially surpassing market forecasts. The Swiss pharmaceutical giant reported revenue of $13.2 billion, representing a
Novartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal
Ad-hoc-Mitteilung gemäss Art. 53 KR
-
Der Nettoumsatz wuchs um 15% (kWk1, 12% USD), das operative Kernergebnis1 verbesserte sich um 27% (kWk, 23% USD)
- Das Umsatzwachstum beruhte auf der
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins. Many huge corporations have announced plans to invest billions in U.S
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
If you have been or are thinking about getting into AbbVie (NYSE: ABBV), there is still time to do so. The AbbVie stock price is in a sustained uptrend
EQS-Adhoc: Merck KGaA: Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme
BioNTech präsentiert auf der AACR-Jahrestagung 2025 klinische und präklinische Daten zu mRNA- und Immunonkologie-Fokus-Programmen
MAINZ, Deutschland, 24. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Association for Cancer
Thermo Fisher Stock: Q1 Beat Overshadowed by Outlook Cut
Thermo Fisher Scientific posted strong first-quarter 2025 results, exceeding analyst expectations with earnings per share of $5.15 against predicted $5.10, and revenue of $10.36 billion versus
Starke Verkäufe von Cresemba® (Isavuconazol) in Japan lösen zweite Umsatzmeilensteinzahlung von Asahi Kasei Pharma an Basilea aus
Allschwil, 24. April 2025
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an
![[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche setzt Wachstumskurs mit Umsatzplus von 6% (CER) im ersten Quartal 2025 fort](/assets/news/news3-b9ff6b4b3cbc4e41e2e273fc3862605edd2b83b4887b24f79ecfa3288a635507.png)
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche setzt Wachstumskurs mit Umsatzplus von 6% (CER) im ersten Quartal 2025 fort
- Konzernverkäufe stiegen um 6%1 zu konstanten Wechselkursen (CER; 7% in CHF) dank hoher Nachfrage nach innovativen Medikamenten und diagnostischen Lösungen.
- Verkäufe der Division Pharma wuchsen um
3 Stocks to Buy Now for Tariff Immunity
There’s a new commodity in the financial markets today, and that’s any stock (or business, for that matter) that carries a certain level of immunity to the recent trade tariffs rolled out by
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), is back in the green in 2025 as of the Apr. 21 close. Shares were down
Medtronic: A Dividend Aristocrat With Stability and Innovation
Investors increasingly seek stable and resilient investments in today's volatile and economically uncertain market. Consequently, it is crucial to
UnitedHealth Group: Pariah to Pole Position to Buy the Dip Levels
UnitedHealth Group Inc. (NYSE: UNH) is a bellwether for the health insurance industry. The company symbolized the flaws in managed care organizations
BioNTech veröffentlicht am 5. Mai 2025 Ergebnisse für das erste Quartal 2025 und informiert über operativen Fortschritt
MAINZ, Deutschland, 22. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 5. Mai 2025, die Ergebnisse für das erste Quartal 2025
Unitedhealth Stock: Dramatic 20% Plunge Shocks Market
UnitedHealth Group shares experienced a catastrophic drop on Thursday, plummeting by over 20% following disappointing first-quarter results. The healthcare giant saw its stock trading as low as
Tariff-Resistant Abbott Laboratories on Track for New Highs
Abbott Laboratories (NYSE: ABT) is not immune to the impact of tariffs on its medical device business. However, the company’s diversified business is tariff-resistant, and moves are being made to
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?
Johnson & Johnson (NYSE: JNJ) delivered a solid earnings report on April 15.
[content-module:CompanyOverview|NYSE:JNJ]On the one hand, the company beat on the top and bottom lines and offered
2 Healthcare Recession-Resistant Stocks Unaffected by Tariffs
The medical sector stocks, notably the health insurance carriers, took a major drubbing in 2024 as Medicare Advantage (MA) plans continued to drive higher utilization costs, eating away at
EQS-Adhoc: Carl Zeiss Meditec erzielt deutliche Gewinnsteigerung im zweiten Quartal 2024/25
Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
Insiders bought large caps like Texas Pacific Land (NYSE: TPL), TKO Group (NYSE: TKO), and Keurig Dr Pepper (NASDAQ: KDP) in Q1, highlighting opportunities in their stocks. The question for Q2 is
Amgen Stock: Sandoz Lawsuit Threatens Blockbuster Drug Revenue
The Swiss generics specialist Sandoz has filed an antitrust lawsuit against Amgen, challenging what it describes as illegal tactics to block competition for Enbrel, Amgen's blockbuster medication
5 Winning Plays Outperforming the S&P This Year
While macroeconomic headwinds, tariffs, inflation, interest rates, and fears of a recession impact the broad market S&P 500, not all stocks are in the same position.
This is a look at five stocks
Verkauf bei Stärke in der Pharmaindustrie, rät Mizuho's Jared Holz
3 Robotics Stocks That Could Benefit From U.S. Manufacturing Boom
With the latest round of tariffs from the Trump administration in early April 2025, investors and business owners alike are reckoning with the idea that the policy is encouraging a repatriation of